Cargando…
Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient
Hemodialysis (HD) is the most common method of chronic kidney failure (CKF) treatment, with 65% of European patients with CKF receiving HD in 2018. Regular two to three HD sessions weekly severely lower their quality of life, resulting in a higher incidence of depression and anxiety, which is presen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133494/ https://www.ncbi.nlm.nih.gov/pubmed/35633796 http://dx.doi.org/10.3389/fpsyt.2022.882860 |
_version_ | 1784713581418250240 |
---|---|
author | Knehtl, Maša Petreski, Tadej Piko, Nejc Ekart, Robert Bevc, Sebastjan |
author_facet | Knehtl, Maša Petreski, Tadej Piko, Nejc Ekart, Robert Bevc, Sebastjan |
author_sort | Knehtl, Maša |
collection | PubMed |
description | Hemodialysis (HD) is the most common method of chronic kidney failure (CKF) treatment, with 65% of European patients with CKF receiving HD in 2018. Regular two to three HD sessions weekly severely lower their quality of life, resulting in a higher incidence of depression and anxiety, which is present in one third to one half of these patients. Additionally, the age of patients receiving HD is increasing with better treatment and care, resulting in more cognitive impairment being uncovered. Lastly, patients with other mental health issues can also develop CKF during their life with need for kidney replacement therapy (KRT). All these conditions need to receive adequate care, which often means prescribing psychotropic medications. Importantly, many of these drugs are eliminated through the kidneys, which results in altered pharmacokinetics when patients receive KRT. This narrative review will focus on common issues and medications of CKF patients, their comorbidities, mental health issues, use of psychotropic medications and their altered pharmacokinetics when used in HD, polypharmacy, and drug interactions, as well as deprescribing algorithms developed for these patients. |
format | Online Article Text |
id | pubmed-9133494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91334942022-05-27 Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient Knehtl, Maša Petreski, Tadej Piko, Nejc Ekart, Robert Bevc, Sebastjan Front Psychiatry Psychiatry Hemodialysis (HD) is the most common method of chronic kidney failure (CKF) treatment, with 65% of European patients with CKF receiving HD in 2018. Regular two to three HD sessions weekly severely lower their quality of life, resulting in a higher incidence of depression and anxiety, which is present in one third to one half of these patients. Additionally, the age of patients receiving HD is increasing with better treatment and care, resulting in more cognitive impairment being uncovered. Lastly, patients with other mental health issues can also develop CKF during their life with need for kidney replacement therapy (KRT). All these conditions need to receive adequate care, which often means prescribing psychotropic medications. Importantly, many of these drugs are eliminated through the kidneys, which results in altered pharmacokinetics when patients receive KRT. This narrative review will focus on common issues and medications of CKF patients, their comorbidities, mental health issues, use of psychotropic medications and their altered pharmacokinetics when used in HD, polypharmacy, and drug interactions, as well as deprescribing algorithms developed for these patients. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9133494/ /pubmed/35633796 http://dx.doi.org/10.3389/fpsyt.2022.882860 Text en Copyright © 2022 Knehtl, Petreski, Piko, Ekart and Bevc. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Knehtl, Maša Petreski, Tadej Piko, Nejc Ekart, Robert Bevc, Sebastjan Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient |
title | Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient |
title_full | Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient |
title_fullStr | Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient |
title_full_unstemmed | Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient |
title_short | Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient |
title_sort | polypharmacy and mental health issues in the senior hemodialysis patient |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133494/ https://www.ncbi.nlm.nih.gov/pubmed/35633796 http://dx.doi.org/10.3389/fpsyt.2022.882860 |
work_keys_str_mv | AT knehtlmasa polypharmacyandmentalhealthissuesintheseniorhemodialysispatient AT petreskitadej polypharmacyandmentalhealthissuesintheseniorhemodialysispatient AT pikonejc polypharmacyandmentalhealthissuesintheseniorhemodialysispatient AT ekartrobert polypharmacyandmentalhealthissuesintheseniorhemodialysispatient AT bevcsebastjan polypharmacyandmentalhealthissuesintheseniorhemodialysispatient |